Investor Relations

A man with his arms crossed


POINT has built a platform to accelerate the next-generation of radiopharmaceuticals with an industry-leading pipeline, in-house manufacturing capabilities, and redundant supply of rare medical isotopes. The management team brings decades of combined experience in radiopharmaceutical clinical development and manufacturing, including 40+ clinical trials, 12 drug approvals, and 8 GMP radiopharmaceutical facilities, and has leveraged prior relationships to assemble one of the industry’s most resilient radioisotope supply chains. The company’s 100%-owned, 80,000 sq ft facility has capacity to commercially supply both North America and Europe for large volume indications. POINT has two late-stage programs one of which is PNT2002, currently being evaluated in the Phase 3 SPLASH study targeting mCRPC, which could lay the cornerstones of the company’s radiopharmaceutical platform. POINT also has an exciting early-stage pipeline which includes a best-in-class FAP-α targeted radioligand PNT2004, a potential pan-cancer target.
Press Release
12 Aug

POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights

Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release. PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters Phase 1 clinical trial.

Press Release
8 Aug

POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022

The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at

Events Calendar


~November 11: Q3 2022 Financial Results


February 22: B. Riley Securities’ Radiation Oncology Investor Day
- Format: Fireside Chat
- Time: 11:30 am ET
- Replay
available here

February 25-27:
SNMMI Mid-Winter Meeting
March 7-9: Cowen & Co. 42nd Annual Healthcare Conference
- Format: Panel Discussion
- Panel: GI/GU Oncology Discussion
- Time: 10:30 am ET
- Webcast link available here

March 14: Oppenheimer & Co. “Radiopharmaceutical Therapies Come of Age”
- Format: Fireside Chat
- Time: 1:00 pm ET

March 15-17: Oppenheimer & Co. 32nd Annual Healthcare Conference 
- Format: Virtual Presentation
- Time: 2:00 pm ET
- Webcast link available here

March 25: Q4 2021 Financial Results 

March 29: "Introduction to Dosimetry for Radiopharmaceuticals"
- Format: POINT Webinar
- Replay available here

April 8-13: American Association for Cancer Research (AACR) Annual Meeting 

April 28: Proxy Filing

May 2: Bloom Burton Healthcare Investor Conference
- Format: Presentation
- Time: 4:00pm ET
- Webcast link available here

May 13: Q1 2022 Financial Results 

May 17: Guggenheim Radiopharmaceuticals Day 2022
- Format: Panel Discussion and Fireside Chat
- Time: 1:30pm ET
- Panel webcast link available here
- Fireside chat available here

May 24: UBS Global Healthcare Conference
- Format: Fireside Chat
- Time: 9:15am ET
- Webcast link available here

June 2: Annual General Meeting (Registration Link)

June 3: Institutional Investor Day

June 9: Jefferies Healthcare Conference
- Format: Fireside Chat
- Time: 10:00am ET
- Webcast link available here

July 13: William Blair Biotech Focus Conference 2022
- Format: Panel Discussion
- Time: 1:00pm ET

July 18: Brookline Capital Markets Newport Biotech Symposium
- Format: 1x1 meetings

~August 12: Q2 2022 Financial Results

December 6: "The First Principles of Radiopharmaceuticals"
- Format: POINT Webinar
- Replay
available here

Stock, Financials & Governance

Financial Reports
Board of Directors
Stock Price
SEC Filings
Section 16 Filings

Governance Documents
Audit Committee Charter
Code of Business Conduct and Ethics
Whistleblower Line Information
Compensation Committee Charter
Corporate Governance Guidelines
Nominating and Corporate Governance Committee Charter

Analyst Coverage
Brookline - Kemp Dolliver
Cowen - Boris Peaker
Jefferies - Suji Jeong
Piper Sandler - Ted Tenthoff
William Blair - Andy Hsieh
Please note, this list of analyst coverage may not complete or up to date. Any opinions, estimates or forecasts regarding performance made by analysts do not represent POINT Biopharma or its management team.



1-833-544-2637 x800

Please do not submit any private or confidential information using this form. Fields marked with an asterisk (*) are required.

Thank you!
Your submission has been received!
Oops! Something went wrong while submitting the form.